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Abstract
Background: An increase in cancer cell invasion and microvascular density is associated with a poorer prognosis
for patients with endometrial cancer. In endometrial adenocarcinoma F-prostanoid (FP) receptor expression is
elevated, along with its ligand prostaglandin (PG)F2a, where it regulates expression and secretion of a host of
growth factors and chemokines involved in tumorigenesis. This study investigates the expression, regulation and
role of a disintegrin and metalloproteinase with thrombospondin repeat 1 (ADAMTS1) in endometrial
adenocarcinoma cells by PGF2a via the FP receptor.
Methods: Human endometrium and adenocarcinoma tissues were obtained in accordance with Lothian Research
Ethics Committee guidance with informed patient consent. Expression of ADAMTS1 mRNA and protein in tissues
was determined by quantitative RT-PCR analysis and immunohistochemistry. Signal transduction pathways
regulating ADAMTS1 expression in Ishikawa cells stably expressing the FP receptor to levels seen in endometrial
cancer (FPS cells) were determined by quantitative RT-PCR analysis. In vitro invasion and proliferation assays were
performed with FPS cells and human umbilical vein endothelial cells (HUVECs) using conditioned medium (CM)
from PGF2a-treated FPS cells from which ADAMTS1 was immunoneutralised and/or recombinant ADAMTS1. The
role of endothelial ADAMTS1 in endothelial cell proliferation was confirmed with RNA interference. The data in this
study were analysed by T-test or ANOVA.
Results: ADAMTS1 mRNA and protein expression is elevated in endometrial adenocarcinoma tissues compared
with normal proliferative phase endometrium and is localised to the glandular and vascular cells. Using FPS cells,
we show that PGF2a-FP signalling upregulates ADAMTS1 expression via a calmodulin-NFAT-dependent pathway
and this promotes epithelial cell invasion through ECM and inhibits endothelial cell proliferation. Furthermore, we
show that CM from FPS cells regulates endothelial cell ADAMTS1 expression in a rapid biphasic manner. Using RNA
interference we show that endothelial cell ADAMTS1 also negatively regulates cellular proliferation.
Conclusions: These data demonstrate elevated ADAMTS1 expression in endometrial adenocarcinoma. Furthermore
we have highlighted a mechanism whereby FP receptor signalling regulates epithelial cell invasion and endothelial
cell function via the PGF2a-FP receptor mediated induction of ADAMTS1.
Background
Endometrial cancer is the most common gynaecological
cancer among women in the Western world [1]. In 2009
the American Cancer Society estimated that there would
be around 42,106 new cases of endometrial cancer
resulting in approximately 7,780 deaths [1]. More than
80% of endometrial cancers are endometrial adenocarci-
nomas of the endometrioid type which originate from
the endometrial lining [2]. Although the etiology of the
disease is poorly understood, the occurrence of endome-
trial cancer has been linked to a variety of genetic and
environmental influences, including age, obesity, dia-
betes and steroid hormones [2-4].
Our laboratory and others have demonstrated ele-
vated expression of prostaglandin-endoperoxide
synthase (PTGS, also called cyclooxygenase or COX)-2,
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sion of prostanoid receptors [7], such as the F-prosta-
noid (FP or PTGFR) receptor in endometrial
adenocarcinomas [7]. Moreover, we have shown that
elevated PGF2a-FP receptor signalling in endometrial
adenocarcinoma leads to upregulation of tumorigenic
genes such as PTGS2 [8] and angiogenic genes such as
FGF2 [9] and VEGF [10] which regulate vascular func-
tion in a paracrine manner [11]. FP receptor can also
regulate the adhesiveness of endometrial adenocarci-
noma cells to the extracellular matrix (ECM) via reor-
ganisation of the actin cytoskeleton and activation of
focal adhesion kinase [7,12]. These findings suggest
that PGF2a-FP receptor signalling plays a multifactorial
role in regulating endometri a la d e n o c a r c i n o m ab yp r o -
moting an environment for angiogenesis and tissue
remodelling to facilitate tumour growth. In addition to
the regulation of cell architecture and adhesion to the
ECM [12,13] the PTGS-PG axis has been shown to
enhance the metastatic potential of tumour cells [14].
Indeed, we have shown that PGF2a,v i at h eF Pr e c e p -
tor, can enhance the motility of endometrial adenocar-
cinoma cells in vitro [12]. In endometrial cancer a
more invasive phenotype and an increase in angiogen-
esis correlate with higher grade, poorly differentiated
cancers [15]. Invasion is an essential cellular process
facilitating tumour cell migration and metastasis. In
breast and pancreatic cancer, the matrix metalloprotei-
nase properties of a disintegrin and metalloprotease
with a thrombospondin repeat (ADAMTS1), along
with its anti-angiogenic role, have been shown to influ-
ence metastasis through the promotion of cellular
migration and invasion [16,17]. ADAMTS1 was first
identified as an inflammatory associated protein that
anchored to the extracellular matrix via heparin depen-
dent mechanisms [18,19]. ADAMTS1 expression is ele-
vated in metastatic breast cancer [17] and pancreatic
cancer, where its expression is associated with inva-
siveness and lymph node metastasis [16]. However, the
expression and role of ADAMTS1 in endometrial ade-
nocarcinoma has not been studied.
Here we investigated the expression and localisation of
ADAMTS1 in endometrial adenocarcinoma and its reg-
ulation by PGF2a via the FP receptor. We found that
ADAMTS1 expression was elevated in the glandular and
vascular compartments in endometrial cancer compared
with normal endometrium. Using in vitro model systems
of Ishikawa endometrial epithelial cells stably expressing
the FP receptor to levels seen in endometrial cancer
(FPS cells) and human umbilical vein endothelial cells
(HUVECs), we found that ADAMTS1 was regulated in
epithelial cells via the PGF2a-FP receptor mediated acti-
vation of the calmodulin-NFAT pathway increasing
epithelial cell invasion and negatively controlling
endothelial cell proliferation.
Methods
Human Tissue
Endometrial cancer tissues and normal endometrial tis-
sues were collected with ethical approval from Lothian
Research Ethics Committee under ethics number LREC/
1999/6/4 as detailed previously [20]. Written informed
consent was obtained from all subjects prior to tissue
collection. Endometrial cancer tissue was obtained from
women undergoing surgery for removal of endometrial
cancer and who had been pre-diagnosed on endometrial
biopsy to have endometrial adenocarcinoma of the
uterus of the endometrioid type. All patients were post-
menopausal women with ages that ranged from 50-71
years of age and presented with complaint of postmeno-
pausal bleeding. The median age of patients was 60.5
years. Cancer biopsies were assessed by a pathologist
and assigned a grade, well differentiated (grade 1; n =
10), moderately differentiated (grade 2; n = 10) or poorly
differentiated (grade 3; n = 10) as outlined in table 1.
None of the carcinoma patients in this study were on
hormone replacement therapy. Normal endometrium
from the proliferative phase of the menstrual cycle
Table 1 Tumour characteristics for well differentiated,
moderately differentiated and poorly differentiated
endometrial adenocarcinomas used in the study
HISTOLOGY FIGO STAGE HISTOLOGY FIGO STAGE
Well Differentiated Ib Poorly Differentiated IIIa
Well Differentiated Ib Poorly Differentiated Ia
Well Differentiated Ia Poorly Differentiated IIIa
Well Differentiated Ic Poorly Differentiated Ib
Well Differentiated IIIa Poorly Differentiated Ib
Well Differentiated Ib Poorly Differentiated IIIa
Well Differentiated Ib Poorly Differentiated Ib
Well Differentiated Ib Poorly Differentiated Ib
Well Differentiated Ia Poorly Differentiated IIIa
Well Differentiated Ia Poorly Differentiated IIb*
Mod Differentiated Ib
Mod Differentiated Ic
Mod Differentiated IIb *
Mod Differentiated IIIa
Mod Differentiated Ic
Mod Differentiated Ic
Mod Differentiated Ic
Mod Differentiated Ia
Mod Differentiated IIb
Mod Differentiated Ib
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Page 2 of 12(n = 10), was collected with an endometrial suction cur-
ette (Pipelle, Laboratoire CCD, France) from women
undergoing surgery for gynecological procedures, includ-
ing surgical sterilisation or abnormal uterine bleeding,
and in whom histological examination of the endome-
trium was normal with no underlying endometrial
pathology. The median age of these women was 30.5
years (range 21-39 yrs). Biopsies were dated according
to stated last menstrual period (LMP) and confirmed by
histological assessment [10] and hormone analysis as
outlined in table 2. After collection, tissue was placed in
RNAlater (Ambion) and stored at -70°C (for RNA
extraction) or fixed in neutral buffered formalin and
wax embedded (for immunohistochemical analysis).
Cell culture
Ishikawa cells stably expressing FP receptor (Ishikawa FPS
cells) to levels observed in endometrial cancer were cul-
tured in Dulbecco’s Modified Eagle’sM e d i u m( D M E M ,
Invitrogen, Paisley, UK) with 10% foetal bovine serum
(FBS) and 1% penicillin/streptomycin as described pre-
viously [10]. Human umbilical vein endothelial cells
(HUVECs) (Lonza, Walkersville, USA) were cultured in
Endothelial Basal Medium (EBM-2) with 2% FBS and
growth supplements (VEGF, FGF, PGDF, IGF, EGF, ascor-
bic acid, heparin and gentamycin) subsequently referred to
as Endothelial Growth Medium (EGM-2) (Lonza, Walk-
ersville, USA). Concentrations of chemical inhibitors were
determined by titration using the manufacturer’sd a t a
sheet as a guide as described in our previous studies
[10,12,20]. Cell viability in the presence of the chemical
compounds used to inhibit specific signal transduction
pathways was assessed using the CellTitre96AQueous One
Solution™ (Promega, Southampton, UK).
Conditioned medium
Conditioned medium (CM) was prepared as described
previously [9]. Briefly, FPS cells were seeded at a density
o f2×1 0
6 cells and allowed to adhere before serum-
starvation for 24 hrs. Thereafter, cells were treated with
20mls of serum free DMEM containing 8.4 μMi n d o -
methacin in the presence of vehicle or 100nM PGF2a
for 24 hrs to create vehicle conditioned medium
(V CM) or PGF2a conditioned medium (P CM). Condi-
tioned medium from three independent experiments
was pooled, aliquoted and stored at -20 °C until
required.
ADAMTS1 immunoneutralisation
ADAMTS1 was immunoneutralised from PGF2a condi-
tioned medium by overnight incubation on a rotar at
4°C, with 1 μg/ml ADAMTS1 antibody (ab28284,
Abcam, Cambridge, UK) in accordance with our pre-
vious study [9]. Immunoglobulin (IgG) from the same
species as the primary antibody was used as a control at
the same concentration. Antibody concentration for
immunoneutralisation was determined empirically by
titration. The immune complex was removed by 4 hr
i n c u b a t i o n ,o nar o t a ra t4 ° C ,w i t h3 0μl of a 50% pro-
tein G plus/protein A agarose mixture (Calbiochem,
Nottingham, UK). Samples were centrifuged at 1500rpm
for 5mins after which the immunoneutralised CM was
aliquoted and stored at -20°C until use.
Taqman quantitative RT-PCR
Taqman RT-PCR was performed as described previously
using sequence specific primers and probes designed to
span an intron [7,21,22]. RNA was extracted, reverse
transcribed and RT-PCR performed using the ABI
Prism 7900 as described previously [9,20]. Analysis of all
samples was performed using the comparative CT
method (ΔΔCT) and expressed relative to a positive
RNA standard (cDNA obtained from pooled endome-
trial cDNA) included in all reactions. The expression of
ADAMTS1 was normalized for RNA loading using ribo-
somal 18 S RNA as an internal standard in the same
reaction. Where data are expressed as fold above con-
trol, the relative ΔΔCT value for the treatment group
(or P CM/P CM and inhibitor) was divided by the
ΔΔCT for the vehicle group (or V CM/V CM and inhi-
bitor). Data are represented as mean ± SEM.
Immunohistochemistry
ADAMTS1 protein expression was localized in endome-
trial adenocarcinoma tissues (n = 15) and proliferative
phase endometrium (n = 5) by immunohistochemistry.
Briefly, five-micron paraffin wax-embedded tissue sec-
tions were cut and mounted onto coated slides (TESPA,
Sigma, Dorset, UK). Sections were dewaxed in xylene,
rehydrated in graded ethanol and washed in water fol-
lowed by TBS (50 mM Tris-HCl, 150 mM NaCl pH7.4)
and blocked for endogenous endoperoxidase (1% H2O2
Table 2 Clinical parameters for normal endometrial
samples from proliferative phase endometrium
HISTOLOGY PROGESTERONE nmol/L ESTRADIOL pmol/L
Proliferative 1.78 400.00
Proliferative 4.80 204.00
Proliferative 3.12 731.00
Proliferative 2.32 1796.00
Proliferative 0.17 989.70
Proliferative 4.26 339.38
Proliferative 2.22 641.37
Proliferative 4.62 525.00
Proliferative 4.57 495.00
Proliferative 2.82 214.00
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Page 3 of 12in methanol). Antigen retrieval was performed by pres-
sure cooking for 2 minutes in 0.01 M sodium citrate
pH6. Sections were blocked using 5% normal swine
serum diluted in PBS with 5% BSA. Tissue sections
were incubated with rabbit anti-human ADAMTS1
polyclonal antibody recognising the amino terminal end
of ADAMTS1 (ab28284, Abcam) (1:100 dilution) over-
night at 4°C. Control sections included the following: no
primary antibody or rabbit IgG. After washing in TBS,
sections were incubated with swine anti-rabbit biotiny-
lated antibody (Dako), followed by streptavidin-horse-
radish peroxidase complex (Dako). Colour reaction was
developed using 3’3 diaminobenzidine (Dako). Sections
were counterstained in haematoxylin. Images were
obtained on a Provis AX70 microscope (Olympus Amer-
ica Inc., NY, USA) using Canon EOS image capture
software (Canon, Reigate, UK).
Immunofluorescence
Dual immunofluorescence for ADAMTS1 and CD31
expression was performed as previously described [9].
Antigen retrieval was performed by pressure cooking for
2 minutes in 0.01 M sodium citrate pH6. Sections were
blocked in 5% normal goat serum diluted in PBS with
5% BSA before incubation with ADAMTS1 antibody
(1:600 dilution). Following overnight incubation at 4°C,
sections were sequentially incubated with goat anti-rab-
bit biotinylated Fab (1:500 dilution) and then tyramide
signal amplification kit (TSA Fluorescein System; 1:50
dilution; Perkin-Elmer). Sections were then microwaved
in 0.01 M citrate buffer for 30 min and endogenous per-
oxidase blocked using hydrogen peroxide. Nonspecific
binding was blocked with 5% normal goat serum. There-
after sections were incubated with rabbit anti-human
CD31 (1:1000 dilution, Sigma) at 4°C overnight. Sections
were again incubated with goat anti-rabbit biotinylated
Fab and tyramide signal amplification kit. Nuclei were
counterstained using Dapi (1:1000 dilution, Molecular
Probes). Sections were mounted in Permafluor (Immu-
notech-Coulter, Marseille, France) and visualised and
photographed using a Carl Zeiss laser scanning micro-
scope LSM510 (Jena, Germany).
Invasion assay
Ishikawa FPS cell invasion was analysed using an 8 μm
polycarbonate membrane Transwell insert (Corning,
NY, USA). Membranes were coated with 20 μlo f
growth factor (GF)-reduced Matrigel (BD Biosciences,
MA, USA) and incubated at 37°C for 30 min to allow
thin layer gel formation. FPS cells (2 × 10
5 cells/well)
were seeded on the membrane (upper chamber) in 500
μl serum free DMEM. In the lower chamber, 750 μlo f
VC M ,PC M ,PC Mi m m u n o n e u t r a l i s e dw i t hI g Go r
ADAMTS1, or recombinant ADAMTS1 (1nM or 10nM
in serum free medium; R&D systems) were added.
Serum free DMEM or complete DMEM were added to
the lower chambers as controls. After 24 hrs incubation
at 37°C in a 5% CO2 atmosphere, cell membranes were
removed and cells were fixed for 30 min in 100% ice
cold methanol. Non-migrated cells on the upper side of
the membranes were removed with a cotton swab and
membranes were stained with haematoxylin. Cells on
the underside of the membranes were photographed
(five fields per membrane at ×100 magnification) using
an inverted microscope and camera (Axiovert 200, Carl
Zeiss, Germany). Fold difference was determined
by dividing the value obtained from P CM or IgG/
ADAMTS1 treated cells by the value obtained from V
CM or serum free treated cells. Data are represented as
fold increase in invasion with V CM or serum free med-
ium = 1 and are presented as mean ± SEM.
Proliferation assay
HUVECs were seeded in 96-well plates at 3000 cells/
well. Following attachment, cell medium was replaced
with EBM1% for 3 hrs. Cells were then treated with
VC M ,PC M ,PC Mi m m u n o n e u t r a l i s e dw i t hI g Go r
ADAMTS1 diluted 1:1 (v/v) with EBM1%. Treatments
were replaced three times during the 96 hr incubation.
Proliferation was determined using the CellTitre96AQu-
eous One Solution™ (Promega) as per manufacturer’s
instructions. Fold difference was determined by dividing
the absorbance obtained by P CM treated cells by the
absorbance obtained by V CM treated cells. Data are
represented as percentage increase in proliferation with
V CM = 100% and are presented as mean ± SEM.
Experiments performed in triplicate.
ADAMTS1 siRNA transfection
ADAMTS1 siRNA was used to silence ADAMTS1
expression in HUVECs. ADAMTS1 Stealth siRNA
duplexes consisting of three non-overlapping sequences
which were commercially validated or control scrambled
non-target siRNA was purchased from Invitrogen. Prior
to the start of experiments the concentration of siRNA
and transfection agent was optimised. Transfection effi-
ciency for HUVECS was determined visually by transfec-
tion of cells with a green fluorescent protein-tagged
expression vector to be approximately 40%. A scrambled
non-target sequence of siRNA was used as a control.
Silencing of ADAMTS1 expression was approximately
50% relative to scrambled control when using a pool of
the three supplied stealth siRNA duplexes at equal ratio.
HUVECs were seeded at 4 × 10
5cells/25cm
2 flask. The
next day, cells were transfected with 20nM control
siRNA or ADAMTS1 siRNA using 5.7 μls i P O R T
Amine Transfection Agent (AppliedBiosystems).
HUVECs were transfectedw i t hc o n t r o ls i R N Aa n d
Keightley et al. BMC Cancer 2010, 10:488
http://www.biomedcentral.com/1471-2407/10/488
Page 4 of 12ADAMTS1 siRNA for 48hrs at 37°C in a 5% CO2 atmo-
sphere after which cells were washed and treated for
12hrs with EGM media before performing proliferation
assays.
Statistical Analysis
T h ed a t ai nt h i ss t u d yw a sa n a l y s e db yT - t e s to r
ANOVA using Prism 4.0 (Graph Pad, San Diego, CA).
A P value less than 0.05 was considered significant in all
cases.
Results
ADAMTS1 expression is elevated in endometrial
adenocarcinoma
We investigated the mRNA expression of ADAMTS1 in
human endometrial adenocarcinoma and normal endo-
metrium from the proliferative phase of the menstrual
cycle by Taqman Quantitative RT-PCR analysis. We
found that the expression of ADAMTS1 was elevated in
all endometrial adenocarcinoma samples compared with
proliferative phase endometrium (Figure 1; P < 0.05).
There was no difference in the levels of ADAMTS1
expression irrespective of the grade or FIGO stage of
endometrial adenocarcinoma, compared with prolifera-
tive phase endometrium.
ADAMTS1 localisation in endometrial adenocarcinoma
and normal endometrium
Next we investigated the site of ADAMTS1 expression
in well, moderately and poorly differentiated endome-
trial adenocarcinomas and proliferative phase endome-
trium. We observed strong immunoreactive staining in
the glandular and vascular compartments of all well,
moderately and poorly differentiated endometrial adeno-
carcinomas (Figure 2A; showing representative tissue
sections). Under the same experimental conditions,
minimal immunoreactivity was observed for ADAMTS1
in proliferative phase endometrium and no immuno-
reactivity was observed in control sections incubated
with IgG from the host species (inset shown for poorly
differentiated endometrial adenocarcinoma).
We confirmed the vascular localisation of ADAMTS1
in endometrial adenocarcinomas by dual immunofluor-
escence immunohistochemistry and confocal laser
microscopy. ADAMTS1 expression (2Bi) co-localised
(merged; 2Biii) with the endothelial cell marker CD31 in
the blood vessels (Figure 2Bii). Nuclear counterstain is
shown in panel 2Biv. No immunoreactivity was observed
in control tissue sections incubated with IgG from the
host species (not shown).
PGF2a -FP receptor signalling regulates ADAMTS1
expression
Since ADAMTS1 and FP receptor [7] are both
expressed within the glandular and vascular compart-
ments in endometrial adenocarcinoma, we investigated
the potential regulation of ADAMTS1 in endometrial
adenocarcinoma cells by PGF2a via the FP receptor
using endometrial adenocarcinoma cells stably expres-
sing the FP receptor to the levels observed in endome-
trial cancer (Ishikawa FPS cells; [10]). FPS cells were
stimulated with vehicle or 100nM PGF2a for the times
indicated in the figure legend. PGF2a stimulation
resulted in a significant time-dependent increase in the
expression of ADAMTS1 mRNA in FPS cells, which
was maximal at 6-8hrs (Figure 3A, P < 0.05).
Consequently, the signalling pathway regulating the
expression of ADAMTS1 was investigated using a panel of
small molecule chemical inhibitors (Figure 3B). FPS cells
were treated with vehicle or 100nM PGF2a in the absence
or presence of the specific FP receptor antagonist AL8810
(50 μM), Gq/11 inhibitor YM-254890 (1 μM), calmodulin
inhibitor W7 (25 μM), NFAT inhibitor INCA6 (40 μM),
c-Src inhibitor PP2 (10 μM), PLC inhibitor U73122 (10
μM), JNK-1 inhibitor JNKi (5 μM) or MEK inhibitor
PD98059 (50 μM; Figure 3B). We found that ADAMTS1
mRNA expression was significantly elevated in response to
PGF2a treatment after 8hrs of agonist stimulation.
Co-incubation of FPS cells with PGF2a and AL8810, YM-
254890, W7 and INCA6 significantly reduced the PGF2a-
FP receptor mediated induction of ADAMTS1 (Figure 3B,
P < 0.05). However, treatment of FPS cells with PGF2a and
PP2, U73122, JNKi or PD98059 had no significant effect
on ADAMTS1 mRNA expression in response to PGF2a
treatment (Figure 3B). These data indicate that in FPS
cells, the upregulation of ADAMTS1 involves PGF2a-FP
signalling to Gq/11, calmodulin and NFAT.
Figure 1 ADAMTS1 mRNA expression in normal proliferative
phase endometrium and endometrial adenocarcinoma.
Expression of ADAMTS1 mRNA in proliferative phase endometrium
(n = 10) and well (n = 10), moderately (n = 10) and poorly
differentiated (n = 10) endometrial adenocarcinoma as determined
by quantitative RT-PCR analysis. * represents statistical significance
compared to proliferative phase endometrium; P < 0.05. Data are
represented as mean ± SEM.
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Page 5 of 12Figure 2 Immunohistochemistry of ADAMTS1 in normal endometrium and endometrial adenocarcinoma. (A) Localisation of the pattern
of expression of ADAMTS1 in tissue samples of well, moderately and poorly differentiated endometrial adenocarcinoma and proliferative phase
endometrium. Representative section of poorly differentiated endometrial adenocarcinoma incubated with IgG from the host species is shown
as a negative control (inset). Black bar indicates 50 μm. (B) Dual immunofluorescence immunohistochemistry was used to co-localise (yellow
channel; iii) the expression of ADAMTS1 (green channel; i) with the endothelial cell specific marker CD31 (red channel; ii) in a representative
sample of poorly differentiated endometrial adenocarcinoma. Dapi was used as the nuclear counterstain (blue channel; iv).
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ADAMTS1
ADAMTS1 has been shown to play a role in cancer cell
metastasis [16,17]. We investigated whether PGF2a via
the FP receptor could promote cell invasion of the ECM,
a critical step in cancer cell metastases, via the induction
of ADAMTS1. FPS cells were treated with vehicle (V) or
100nM PGF2a (P) for 24hrs to generate conditioned
medium (CM). Using a modified Boyden chamber assay
[23], we found that P CM significantly increased invasion
of FPS cells through a layer of ECM compared to cells
treated with control V CM (Figure 4A, P < 0.05).
Furthermore, treatment of FPS cells with P CM in which
ADAMTS1 had been immunoneutralised (P CM
+ADAMTS1Ab), significantly inhibited FPS cell invasion
compared with cells treated with P CM incubated with
I g G( PC M + I g G )o rPC Ma l o n e( F i g u r e4 A ,P<0 . 0 5 ) .
We confirmed that ADAMTS1 enhanced FPS cell inva-
sion using recombinant ADAMTS1 protein. We found
that recombinant ADAMTS1 at both low (1nM) or high
(10nM) doses significantly increased FPS cell invasion
compared to control serum free medium (Figure 4B, P <
0.05). Furthermore there was no significant difference
between ADAMTS1-induced FPS cells invasion at either
concentration. This indicates that ADAMTS1 in the
P CM, induced in response to PGF2a-FP receptor signal-
ling, acts in a paracrine manner to promote FPS cell
invasion through ECM.
The paracrine action of ADAMTS1 in P CM-induced
endothelial cell proliferation
Since we found ADAMTS1 immunolocalised in the vas-
culature of endometrial adenocarcinoma (Figure 2B), we
investigated the regulation of ADAMTS1 in endothelial
cells in response to CM from FPS cells. We treated
endothelial cells with V CM or P CM for the time indi-
cated in the figure legend and investigated endothelial
ADAMTS1 expression by quantitative RT-PCR analysis
(Figure 5A). We found a dramatic elevation in endothe-
lial ADAMTS1 mRNA expression at 1 and 4hrs of P CM
treatment (Figure 5A; P < 0.05). We investigated the role
of endothelial ADAMTS1 on endothelial cell prolifera-
tion as it has been described previously to be a potent
anti-angiogenic factor [24]. We found that treatment of
HUVECs with P CM significantly increased endothelial
cell proliferation compared to V CM. Immunoneutralisa-
tion of ADAMTS1 from P CM (P CM+ADAMTS1Ab)
further elevated endothelial cell proliferation compared
with P CM alone or P CM incubated with IgG in place of
neutralising antibody (P CM+IgG; Figure 5B, P < 0.05).
Since ADAMTS1 is also expressed and produced in
endothelial cells (Figure 2B) we investigated the role of
endogenously produced endothelial ADAMTS1 on cellu-
lar proliferation using RNA interference. We used a
cocktail of three commercially available validated siRNAs
and found that we could suppress endogenous
ADAMTS1 expression in HUVECs by approximately
50% when compared to a control non-target siRNA or
untransfected cells (Figure 5C). Using this approach, we
found that silencing of endothelial ADAMTS1 in
HUVECs with ADAMTS1 siRNA prior to treatment with
P CM also enhanced the proliferative effects compared
with HUVECS transfected with control siRNA (Figure
5D, P < 0.05). These data suggest a dual mechanism for
regulation of endothelial cell function by ADAMTS1
released from epithelial cells and endothelial cells.
Figure 3 ADAMTS1 mRNA expression in PGF2a treated FPS cells. (A) FPS cells were treated with vehicle or 100nM PGF2a for 0, 2, 4, 6, 8, 12,
16, 24, 36, 48, 64 and 72 hrs and subjected to quantitative RT-PCR analysis for ADAMTS1. (B) FPS cells were treated for 8hrs with vehicle or
100nM PGF2a in the absence/presence of the FP receptor antagonist (AL8810), Gq/11 inhibitor (YM-254890), calmodulin inhibitor (W7), NFAT
inhibitor (INCA6), c-Src inhibitor (PP2), PLC inhibitor (U73122), JNK inhibitor (JNKi) or MEK inhibitor (PD98059) and mRNA expression of ADAMTS1
was determined by quantitative RT-PCR analysis. * represents statistical significance; P < 0.05. Data are represented as mean ± SEM from at least
3 independent experiments.
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Metastasis is one of the hallmarks of cancer, where neo-
plastic cells migrate away from the solid tumour, invade
through ECM, and become dispersed around the body
via the blood and lymphatics [25]. The process of
metastasis is generally associated with poor prognosis
and survival rates [26]. Although the mechanisms that
regulate cancer metastasis are multiple, a link between
the PTGS-prostaglandin pathway in breast and colon
cancers has been established [14,27]. The specific mole-
cular mechanisms and effector molecules which mediate
metastasis, especially in the context of endometrial can-
cers are however poorly defined.
In this study, we investigated the expression, regula-
tion and potential role of a disintegrin and metallopro-
tease with a thrombospondin repeat 1 (ADAMTS1) in
endometrial adenocarcinomas. In breast and pancreatic
cancer, ADAMTS1 has been shown to promote metas-
tasis by enhancing cellular migration and invasion
[16,17,28]. In the present study, we found that the
expression of ADAMTS1 was upregulated coincident
with the FP receptor [7] in well, moderately and poorly
differentiated endometrial adenocarcinoma samples
compared to normal endometrium from the proliferative
phase of the menstrual cycle. Since the endometrium of
post-menopausal women is no longer under normal
hormonal control, is atrophic and often not attainable,
we chose normal proliferative phase endometrium as
our comparator. This is the phase of the menstrual
cycle which exhibits rapid cellular proliferation, differen-
tiation and tissue remodelling and is the phase of the
menstrual cycle with the highest level of FP receptor
expression [29].
We localised the site of expression of ADAMTS1 to
the neoplastic epithelial and vascular cells of endome-
trial cancer tissues by immunohistochemistry and confo-
cal laser microscopy. This pattern of expression in
endometrial adenocarcinomas is similar to the expres-
sion profile for ADAMTS1 in secretory phase human
endometrium as reported by Ng and colleagues, where
expression is observed in the glandular epithelial and
stromal cells [30]. In contrast to this latter study that
reports readily detectable levels of ADAMTS1 through-
out the menstrual cycle [30], in our study we found
minimal immunoreactivity for ADAMTS1 in prolifera-
tive phase endometrium compared with the different
grades of endometrial adenocarcinomas. Since the anti-
body concentration in our study was optimised for
staining in the cancer tissues, we believe that the mini-
mal immunostaining observed in the proliferative phase
endometrium reflects the lower amount of ADAMTS1
protein in the normal endometrium compared with
endometrial cancer and confirms our observations of
differential mRNA expression in cancer and normal
endometrial tissue presented in figure 1.
In order to investigate the regulation of ADAMTS1 in
endometrial adenocarcinoma cells by the FP receptor
and its potential role in endometrial cancer cell inva-
sion, we used an endometrial cancer cell line stably
expressing the FP receptor to the levels observed in
endometrial adenocarcinoma (FPS cells) [10]. This in
vitro approach has previously been used extensively to
Figure 4 The paracrine action of ADAMTS1 on FPS cell invasion. (A) FPS cells were treated with V CM, P CM or P CM incubated with IgG or
ADAMTS1 antibody for immunoneutralisation. Cell invasion through a monolayer of extracellular matrix was assessed after 24 hrs using a Boyden
chamber assay. * represents statistical significance; P < 0.05. (B) FPS cells were treated with control (serum-free medium; SF) or SF medium with
the addition of 1 or 10nM recombinant ADAMTS1 and cell invasion through a monolayer of extracellular matrix was assessed. * represents
statistical significance of treated group relative to control; P < 0.05. Data are represented as mean ± SEM from at least 3 independent
experiments.
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robustly parallels the ex vivo effects of PGF2a on endo-
metrial adenocarcinoma explants [9,10]. Using a panel
of chemical inhibitors we found that ADAMTS1 expres-
sion was regulated by PGF2a-FP receptor signalling in
FPS cells independently of the MAPK pathway via the
Gq-mediated activation of calmodulin and NFAT.
When NFAT is dephosphorylated by effector signal-
ling molecules, it translocates to the nucleus where it
regulates target gene transcription [32]. NFAT is known
to complex with other transcription factors, including
activator protein 1 (AP1) within the transcriptome
where it can regulate the expression of factors involved
in cancer cell invasion [27,33].
Figure 5 ADAMTS1 regulates vascular function in vitro. (A) HUVECs were treated with V CM or P CM for 0.5, 1, 2, 3, 4, 6, 16 and 24 hrs and
ADAMTS1 mRNA expression was determined by quantitative RT-PCR analysis. (B) HUVECs were treated with V CM, P CM or P CM incubated
with IgG or ADAMTS1 antibody for immunoneutralisation. Endothelial cell proliferation was assessed as described in the materials and methods.
(C) HUVECs were transfected with control siRNA or ADAMTS1 siRNA for 48hrs or left untransfected for 48 hours. Thereafter ADAMTS1 mRNA
expression was investigated by quantitative RT-PCR analysis. (D) HUVECs were transfected with control siRNA or ADAMTS1 siRNA for 48hrs.
Subsequently, HUVECs were treated with V CM or P CM and proliferation assays were performed as described in the materials and methods. *
represents statistical significance; P < 0.05. Data are represented as mean ± SEM from at least 3 independent experiments.
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ing FPS cells with FPS cell conditioned medium from
which ADAMTS1 was immunoneutralised or treatment
with recombinant ADAMTS1 protein. We have shown
with both treatments that invasion of FPS cells through
the ECM is mediated by ADAMTS1. These findings are
similar to recent reports by Hatipoglu and colleagues
and Krampert and colleagues, that demonstrate a role
for ADAMTS1 in regulating cell movement [34,35].
Interestingly these latter studies report differential
effects of ADAMTS1 depending on concentration and
oxygen levels. For example, high concentrations of
ADAMTS1 inhibits fibroblast migration by binding to
and inactivating fibroblast growth factor- 2 under nor-
moxic conditions and inhibits endothelial cell migration
under hypoxic conditions [34,35]. However, in our study
we found similar effects for ADAMTS1 in promoting
FPS cell migration through a thin layer of ECM at both
low (1nM) and high (10nM) concentrations under
serum-free normoxic conditions. Although our study
has not addressed the molecular mechanisms whereby
ADAMTS1 regulates FPS cell invasion, several
substrates have now been identified for ADAMTS1,
including proteoglycans and aggrecan [36,37].
ADAMTS1 has been shown to cleave extracellular
matrix proteins, such as syndecan 4 and semaphorin 3C,
and to utilise metalloproteinase-dependent mechanisms
to influence cell adhesion and migration [38-40].
Furthermore, upregulation of ADAMTS1 by ETS tran-
scription factor gene (ERG) has been shown to contri-
bute to an invasive phenotype in prostate cancer [41]. It
is thus likely that ADAMTS1-mediated endometrial cell
invasion is regulated via similar mechanisms following
its release from epithelial cells in response to PGF2a-FP
receptor signalling to NFAT.
In addition to regulating cellular invasion and metas-
tasis, ADAMTS1 is also a potent anti-angiogenic factor
[ 2 4 ] .T u m o u ra n g i o g e n e s i si st i g h t l yr e g u l a t e db yab a l -
ance between pro-angiogenic and anti-angiogenic factors
[42]. In our previous study we highlighted a role for the
pro-angiogenic fibroblast growth factor-2, secreted from
endometrial adenocarcinoma cells, in regulating
endothelial network formation and proliferation [11].
Anti-angiogenic factors such as thrombospondin and
Figure 6 Schematic diagram representing the role of ADAMTS1 in epithelial cell invasion and endothelial cell proliferation. ADAMTS1
expression is elevated in the epithelial cells of endometrial adenocarcinoma by PGF2a-FP receptor signalling to the calmodulin-NFAT pathway. In
turn ADAMTS1 acts in an autocrine/paracrine manner on tumour epithelial cells to regulate epithelial cell invasion through ECM. Moreover,
ADAMTS1 secreted from epithelial cells acts in a paracrine manner on endothelial cells to inhibit cellular proliferation. In addition factors present
in the conditioned medium from PGF2a- treated epithelial cells upregulates endothelial ADAMTS1 which in turn can act in an autocrine/
paracrine manner to inhibit endothelial cell proliferation.
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pro-angiogenic factors to counterbalance endothelial cell
proliferation in vitro and angiogenesis in vivo [43-47].
In accordance with this, we found that immunoneutrali-
sation of ADAMTS1 from conditioned medium from
PGF2a-treated FPS cells enhanced endothelial cell prolif-
eration compared with conditioned medium alone, indi-
cating that ADAMTS1 is an inhibitor of endothelial cell
proliferation. Similar anti-angiogenic effects for
ADAMTS1 have been reported in other systems. For
example, ADAMTS1 expression in bovine aortic
endothelial cells has been shown to inhibit endothelial
cell proliferation and angiogenesis in vivo [24,48].
Furthermore, we found that endothelial cell expression
of ADAMTS1 was also rapidly induced by conditioned
medium from PGF2a-treated FPS cells in a biphasic
manner, which was reciprocal to the expression pattern
of the pro-angiogenic fibroblast growth factor 2 reported
in our previous study [11]. This rapid time frame of
induction of ADAMTS1 in endothelial cells, within 1
hour, is similar to recent reports for induction of this
protein by hypoxia, indicating that it is likely to be an
early response gene induced to tightly regulate endothe-
lial cell proliferation [34]. Using RNA interference, we
have shown that silencing ADAMTS1 expression in
endothelial cells also enhanced endothelial cell prolifera-
tion. These data indicate a dual mechanism for the reg-
ulation of endothelial cell function by ADAMTS1
released from neoplastic epithelial cells and endothelial
cells.
Conclusion
As summarised in Figure 6, this study presents novel
data demonstrating that PGF2a-FP receptor signalling in
endometrial adenocarcinoma cells upregulates
ADAMTS1 expression via a Gq-calmodulin-NFAT-
dependent pathway. In turn ADAMTS1 acts in an auto-
crine/paracrine manner on tumour epithelial cells to
regulate epithelial cell invasion through ECM. Moreover,
it shows that ADAMTS1 acts in a paracrine manner on
endothelial cells to inhibit cellular proliferation. In addi-
tion factors present in the conditioned medium from
PGF2a- treated epithelial cells upregulate endothelial
ADAMTS1 which in turn can act in an autocrine/para-
crine manner to inhibit endothelial cell proliferation.
Taken together our data highlight a mechanism whereby
ADAMTS1, induced by PGF2a-FP signalling, regulates
tumour cell invasion and endothelial cell proliferation in
endometrial adenocarcinoma.
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